4773392
Last Update Posted: 2025-11-10
Recruiting has ended
All Genders accepted | 18 Years-85 Years |
20 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
The purpose of this study is to determine if the combination of once-daily tacrolimus extended-release (EnvarsusXR) and Azathioprine is non inferior with respect to the composite outcome of acute rejection, graft and patient survival as compared to a combination of twice-daily immediate release tacrolimus and mycophenolate mofetil/mycophenolic acid.
The purpose of this study is to determine if the combination of once-daily tacrolimus extended-release (EnvarsusXR) and Azathioprine is non inferior with respect to the composite outcome of acute rejection, graft and patient survival as compared to a combination of twice-daily immediate release tacrolimus and mycophenolate mofetil/mycophenolic acid.
Eligibility
Relevant conditions:
Kidney Transplantation
Kidney Transplant Rejection
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Melissa Ramos, BSN
Melissa.Ramos@med.usc.edu
323-442-7983
Data sourced from ClinicalTrials.gov